Zura Bio Taps Tourmaline Vet Kulkarni as CEO for Pivotal Readouts

HENDERSON, Nev. – January 21, 2026 – Zura Bio has appointed immunology industry veteran Sandeep Kulkarni, M.D., as its new Chief Executive Officer, a strategic move that places a proven leader at the helm as the company enters a critical 18-month period. The clinical-stage biotechnology firm (Nasdaq: ZURA) is anticipating potentially transformative clinical trial results for its lead drug candidate, positioning the leadership change as a pivotal moment in its growth trajectory.

Dr. Kulkarni, who has served on Zura’s Board of Directors since its Nasdaq debut in March 2023, officially takes the CEO position today. He succeeds Robert Lisicki, who has resigned as CEO and Director following a medical leave of absence that began in October 2025. Kim Davis, J.D., who capably led the company as Interim CEO during the transition, will resume her key roles as Chief Operating Officer, Chief Legal Officer, and Corporate Secretary, ensuring operational continuity.

“We are honored to have Sandeep lead Zura as we enter this important period for our company, with two potentially transformative readouts over the next 18 months,” said Amit Munshi, Chairman of the Board of Directors. “He brings a strong combination of scientific, operational, and strategic leadership.”

A Leader with a Record of Success

Dr. Kulkarni is no stranger to navigating the high-stakes world of biotechnology development and strategy. His appointment is widely seen as a significant vote of confidence in Zura’s pipeline, largely due to his recent and highly successful tenure as co-founder and CEO of Tourmaline Bio. He guided Tourmaline from its inception through a successful acquisition by pharmaceutical giant Novartis, a deal that closed in October 2025. This track record of creating and realizing shareholder value is a key asset as Zura approaches its own major value inflection points.

His long-standing involvement with Zura provides him with an insider’s perspective. Having served as a director of the company’s predecessor since March 2022 and later on Zura’s board, including on its Compensation and Audit Committees, Dr. Kulkarni possesses a deep, pre-existing understanding of the company's science and strategy.

“His service on our Board has provided him with a strong understanding of our programs and their transformative potential, positioning him well to lead Zura,” Mr. Munshi noted. Dr. Kulkarni’s experience also includes senior roles at Immunovant, Roivant Sciences, KVP Capital, and The Boston Consulting Group, underpinned by a medical degree from the University of California, San Francisco and an undergraduate degree from Harvard University.

High Stakes Pinned on a First-in-Class Antibody

The intense focus on Zura Bio centers on its lead asset, tibulizumab. This is a first-in-class bispecific antibody engineered to simultaneously block two key pathways in autoimmune disease: Interleukin-17 (IL-17) and B-cell Activating Factor (BAFF). By targeting both T-cell and B-cell driven inflammation, tibulizumab has the potential to offer a more comprehensive treatment than single-pathway inhibitors for complex autoimmune conditions.

“Our lead program, tibulizumab, is the first- and only-in-class bispecific antibody blocking the IL-17 and BAFF pathways, each of which has been validated in multiple autoimmune diseases,” Dr. Kulkarni stated. “Tibulizumab is one of the most advanced bispecific antibodies in development for treating autoimmune diseases, and we have the potential to lead this paradigm shift.”

Zura is currently running two crucial Phase 2 trials:

• TibuSHIELD: This global study is evaluating tibulizumab in approximately 180 adults with moderate to severe hidradenitis suppurativa (HS), a debilitating chronic skin disease with significant unmet medical need. The primary endpoint measures the reduction in painful abscesses and nodules. Topline results from this trial are anticipated in the third quarter of 2026, representing the first of the major readouts.

• TibuSURE: This trial is assessing the drug in up to 80 patients with systemic sclerosis (SSc), a rare and often fatal autoimmune disease characterized by widespread tissue fibrosis. The study's primary goal is to measure the reduction in skin fibrosis, a key marker of disease progression. The trial is estimated to complete in May 2027.

Success in either of these indications could fundamentally change the treatment landscape for patients and dramatically alter the valuation and future of Zura Bio.

Navigating the Financial Gauntlet

Dr. Kulkarni takes leadership of a company that has captured significant investor interest but faces the inherent financial pressures of clinical-stage drug development. Zura’s stock (ZURA) has surged an impressive 140% over the past year, and the company boasts a market capitalization of approximately $326 million. Analyst consensus remains strong, with a majority rating the stock a “Buy” or “Strong Buy.”

Financially, the company is in a relatively stable position, holding more cash than debt and possessing a current ratio of 5.58, indicating solid short-term liquidity. However, like many of its peers, Zura is burning through its reserves, reporting a negative free cash flow of $53.5 million over the last twelve months. A key part of Dr. Kulkarni’s mandate will be to manage this capital burn effectively to ensure the company has a sufficient runway to reach its critical clinical milestones without dilutive financing events at inopportune times. The upcoming trial results are the key to unlocking the company’s next phase of growth and securing its long-term financial health.

A Seamless Transition

The leadership transition has been structured to ensure stability. The board expressed its gratitude for the departing CEO and the interim leader. “We thank Robert Lisicki for his leadership and meaningful contributions during a formative period in Zura’s growth and wish him the very best,” Mr. Munshi said. “We are also grateful to Kim Davis for her leadership as Interim CEO, which ensured continuity during the transition.”

With Dr. Kulkarni’s deep familiarity with the company and Ms. Davis’s continued presence in the C-suite, Zura Bio aims to project an image of stability and focused execution. As the company counts down to its first major data reveal later this year, all eyes will be on its new chief executive to navigate the complex scientific, regulatory, and financial path ahead.